Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers | Zendy

Wattana Sukeepaisarnjaroen | Zendy; Tri Nhut Pham | Zendy; Tawesak Tanwandee | Zendy; Saroja Nazareth | Zendy; Sam Galhenage | Zendy; Lindsay Mollison | Zendy; Leanne Totten | Zendy; Alan Wigg | Zendy; Rosalie Altus | Zendy; Anton Colman | Zendy; B. Morales | Zendy; Sue Mason | Zendy; Tracy LevettJones | Zendy; Nadine Leembruggen | Zendy; Vince Fragomelli | Zendy; Cheryl Sendall | Zendy; Richard Guan | Zendy; D.S. Sutedja | Zendy; Soek Siam Tan | Zendy; Yock Young Dan | Zendy; Yin Mei Lee | Zendy; W Luman | Zendy; Eng Kiong Teo | Zendy; Yin Min Than | Zendy; Teerha Piratvisuth | Zendy; Seng Gee Lim | Zendy

Open Access

Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers

Author(s) -

Wattana Sukeepaisarnjaroen,

Tri Nhut Pham,

Tawesak Tanwandee,

Saroja Nazareth,

Sam Galhenage,

Lindsay Mollison,

Leanne Totten,

Alan Wigg,

Rosalie Altus,

Anton Colman,

B. Morales,

Sue Mason,

Tracy LevettJones,

Nadine Leembruggen,

Vince Fragomelli,

Cheryl Sendall,

Richard Guan,

D.S. Sutedja,

Soek Siam Tan,

Yock Young Dan,

Yin Mei Lee,

W Luman,

Eng Kiong Teo,

Yin Min Than,

Teerha Piratvisuth,

Seng Gee Lim

Publication year - 2015

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v21.i28.8660

Subject(s) - boceprevir , medicine , ribavirin , cirrhosis , gastroenterology , adverse effect , hepatitis c , hepatitis c virus , decompensation , pegylated interferon , immunology , virus

To examined the efficacy and safety of treatment with boceprevir, PEGylated-interferon and ribavirin (PR) in hepatitis C virus genotype 1 (HCVGT1) PR treatment-failures in Asia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research